home / stock / qure / qure quote
Last: | $4.56 |
---|---|
Change Percent: | -0.42% |
Open: | $4.77 |
Close: | $4.56 |
High: | $4.78 |
Low: | $4.48 |
Volume: | 635,793 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.56 | $4.77 | $4.56 | $4.78 | $4.48 | 635,793 | 04-24-2024 |
$4.75 | $4.82 | $4.75 | $4.895 | $4.735 | 461,596 | 04-23-2024 |
$4.82 | $4.7 | $4.82 | $4.87 | $4.67 | 380,094 | 04-22-2024 |
$4.67 | $4.71 | $4.67 | $4.75 | $4.61 | 547,860 | 04-19-2024 |
$4.71 | $4.66 | $4.71 | $4.76 | $4.655 | 440,845 | 04-18-2024 |
$4.67 | $4.73 | $4.67 | $4.765 | $4.6099 | 825,647 | 04-17-2024 |
$4.7 | $4.71 | $4.7 | $4.8 | $4.65 | 432,949 | 04-16-2024 |
$4.74 | $4.79 | $4.74 | $4.825 | $4.6212 | 669,356 | 04-15-2024 |
$4.78 | $4.96 | $4.78 | $5.03 | $4.72 | 1,220,570 | 04-12-2024 |
$5.03 | $5.09 | $5.03 | $5.16 | $4.975 | 533,128 | 04-11-2024 |
$5.02 | $4.99 | $5.02 | $5.06 | $4.95 | 1,009,779 | 04-10-2024 |
$5.2 | $5.23 | $5.2 | $5.31 | $5.12 | 483,327 | 04-09-2024 |
$5.2 | $5.17 | $5.2 | $5.22 | $5 | 563,859 | 04-08-2024 |
$5.15 | $5.15 | $5.15 | $5.25 | $5.08 | 795,439 | 04-05-2024 |
$5.2 | $5.41 | $5.2 | $5.4799 | $5.155 | 427,148 | 04-04-2024 |
$5.32 | $4.96 | $5.32 | $5.33 | $4.96 | 605,546 | 04-03-2024 |
$4.98 | $5.05 | $4.98 | $5.12 | $4.98 | 751,339 | 04-02-2024 |
$5.21 | $5.2 | $5.21 | $5.22 | $4.982 | 846,431 | 04-01-2024 |
$5.2 | $5.35 | $5.2 | $5.4 | $5.16 | 767,714 | 03-29-2024 |
$5.2 | $5.35 | $5.2 | $5.4 | $5.16 | 767,714 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
uniQure N.V. Company Name:
QURE Stock Symbol:
NASDAQ Market:
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter fin...
~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease; Up to three years of follo...